FY2024 EPS Estimates for GoodRx Holdings, Inc. Lowered by Analyst (NASDAQ:GDRX)

GoodRx Holdings, Inc. (NASDAQ:GDRX) – Investment analysts at Leerink Partnrs lowered their FY2024 earnings per share estimates for GoodRx in a note issued to investors on Tuesday, October 1st. Leerink Partnrs analyst M. Cherny now anticipates that the company will post earnings per share of $0.13 for the year, down from their prior forecast of $0.14. The consensus estimate for GoodRx’s current full-year earnings is $0.14 per share. Leerink Partnrs also issued estimates for GoodRx’s Q1 2025 earnings at $0.05 EPS, Q2 2025 earnings at $0.06 EPS, Q3 2025 earnings at $0.06 EPS, Q4 2025 earnings at $0.06 EPS and FY2026 earnings at $0.30 EPS.

GoodRx (NASDAQ:GDRX) last announced its earnings results on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The company had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. During the same quarter last year, the business posted $0.02 earnings per share. The business’s quarterly revenue was up 5.7% on a year-over-year basis.

A number of other analysts have also commented on GDRX. Morgan Stanley boosted their price target on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a report on Monday, June 10th. UBS Group cut their target price on GoodRx from $9.00 to $8.50 and set a “neutral” rating on the stock in a research note on Friday, August 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $10.00 price target on shares of GoodRx in a research note on Friday, August 16th. Raymond James raised shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 price objective on the stock in a research report on Friday, August 9th. Finally, Citigroup reduced their target price on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $9.36.

GoodRx Stock Down 0.1 %

Shares of GDRX stock opened at $6.93 on Wednesday. The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of -693.00, a P/E/G ratio of 3.38 and a beta of 1.38. GoodRx has a 12-month low of $4.14 and a 12-month high of $9.26. The firm has a fifty day moving average of $7.73 and a 200-day moving average of $7.57. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96.

Institutional Investors Weigh In On GoodRx

Several hedge funds have recently added to or reduced their stakes in GDRX. Beacon Capital Management LLC bought a new position in shares of GoodRx in the first quarter valued at about $28,000. Plato Investment Management Ltd acquired a new position in GoodRx in the 2nd quarter valued at about $43,000. Gerber LLC bought a new position in GoodRx in the 4th quarter valued at about $75,000. Dark Forest Capital Management LP acquired a new stake in GoodRx during the second quarter worth approximately $86,000. Finally, EntryPoint Capital LLC boosted its holdings in shares of GoodRx by 165.2% during the first quarter. EntryPoint Capital LLC now owns 18,538 shares of the company’s stock worth $132,000 after acquiring an additional 11,548 shares during the period. Institutional investors and hedge funds own 63.77% of the company’s stock.

Insider Activity

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 4.17% of the stock is owned by insiders.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.